Compare ENTX & VRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | VRA |
|---|---|---|
| Founded | 2010 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 156.6M |
| IPO Year | 2015 | 2010 |
| Metric | ENTX | VRA |
|---|---|---|
| Price | $3.11 | $7.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 569.4K | 474.4K |
| Earning Date | 11-17-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.47 |
| EPS | ★ 0.22 | N/A |
| Revenue | $42,000.00 | ★ $416,097,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.56 |
| P/E Ratio | $13.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $1.39 |
| 52 Week High | $4.20 | $7.13 |
| Indicator | ENTX | VRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 81.50 |
| Support Level | $2.64 | $3.05 |
| Resistance Level | $3.26 | N/A |
| Average True Range (ATR) | 0.24 | 0.35 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 70.00 | 90.97 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.